Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas nisl neque, tincidunt ut risus ac, pulvinar aliquet orci. Morbi ultricies lacus a purus maximus.

References:

1. Grammatico S, Cesini L, Petrucci MT. Managing treatment-related peripheral neuropathy in patients with multiple myeloma. Blood Lymphat Cancer 2016; 6:37-47.

2. Montefusco V, Cafro AM, Margiotta Casaluci G, Patriarca F, Mina R, D’Agostino M, et al. P39 DEDALO: PHASE II STUDY OF DARATUMUMAB PLUS POMALIDOMIDE AND DEXAMETHASONE (DPD) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND 17P DELETION. Hemasphere 2023;7(Suppl ):32-33.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171702/

3. Sonneveld P, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, et al. Overall Survival with Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial. J Clin Oncol 2023;41(8):1600-1609.

4. Costa LJ et al. Ciltacabtagene autoleucel vs standard of care in patients with functional high-risk multiple myeloma: CARTITUDE-4 subgroup analysis. J Clin Oncol 2024. 42:16. https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.7504